Formula I Compounds Inhibiting SHP2 Phosphatase Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective inhibitors for the Src Homology-2 phosphatase (SHP2) activity, which is implicated in various diseases such as Noonan Syndrome, leukemia, and cancers, highlighting the need for compounds that can modulate SHP2 activity to prevent or inhibit disease pathology.
Innovation Solution
Development of specific compounds of Formula I, which include a range of substituents and structural features, designed to inhibit SHP2 activity by targeting its catalytic site, thereby preventing aberrant signaling pathways associated with diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of diseases associated with SHP2 activity is attempted, but effective inhibition of SHP2 activity is not achieved
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that specifically bind to and inhibit SHP2 phosphatase activity. These compounds act as mediators between the therapeutic goal and the molecular target, blocking the aberrant signaling pathways without requiring direct genetic modification or complex biological agents.
Solution Approach 2:
The invention changes the chemical and structural parameters of the therapeutic agents by developing novel compound structures with specific molecular features. The compounds are designed with particular functional groups, ring structures, and substituent patterns that enable selective binding to SHP2, thereby changing the effectiveness parameter of SHP2 inhibition from inadequate to therapeutic.
2Object-affected harmful factors
If SHP2 activity is not inhibited, then cellular signaling continues unabated, but disease pathology progresses
Solution Approach 1:
The patent employs compounds that preemptively block SHP2 catalytic activity before aberrant signaling can propagate. By inhibiting the phosphatase activity at its source, the compounds prevent downstream signaling events that would otherwise contribute to disease progression, acting in advance to stop the harmful cascade.
Solution Approach 2:
The invention effectively extracts or removes the harmful phosphatase activity from the system by selectively inhibiting SHP2. The compounds bind to the catalytic site and prevent substrate dephosphorylation, thereby taking out the problematic enzymatic function while leaving other cellular processes intact.
Data Source
AI summary
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.